In the beginning of the fight with COVID-19, doctors attempted to use regular combinations of several antiviral drugs, including oseltamivir (anti-flu medication), lopinavir (against HIV infections), and ganciclovir (against cytomegalovirus and Herpes viruses). These proved to be ineffective with varying levels of minimal to no success and the medical world realized that we would need much bigger and more effective treatments.
One thing we all need to keep in mind is that there are no FDA-approved drugs designed for COVID-19. By now, there are two in-use "experimental" therapies.
REMDESIVIR Developed by Gilead as an investigational nucleotide analog against Ebola virus. Nucleotide analogs contain a modified nucleotide base that is incorporated into the viral genome and disrupts its replicational apparatus. It shows some efficacy in inhibiting the SARS-CoV2 growth in infected cells. Remdesivir has not been approved anywhere in the world as a legitimate drug against SARS-CoV2. 6 different clinical trials (Gilead 1, Gilead 2, NIAID, INSERM, China 1, China 2) at either phases 2 (testing the biological effect of a drug) or 3 (evaluating the clinical value of a drug) have just begun. Expected results should be known by the end of May.
HYDROXYCHLOROQUINE and CHLOROQUINE Hydroxychloroquine has traditionally been used for rheumatoid arthritis, systemic lupus erythematosus, and porphiria cutanea tarda. Chloroquine has primarily been used for treatment of malaria. Both drugs have shown a satisfying efficacy against SARS-CoV and SARS-CoV2, with hydroxychloroquine showing more promising signs as a valid drug against COVID-19. They are not officially approved by FDA, but they have started to be used on an uncontrolled basis in many countries, including the United States. Hydroxychloroquine is used in a combination with azithromycin (an antibiotic) and the preliminary clinical results are promising. As of March 28th, Clinical studies have begun for the drugs.
By now, there are 202 ongoing, active, or withdrawn clinical trials (check them all out here). This is the biggest biomedical joined-assault against a human disease in our history. Almost every biotech company (including Babu™) is trying to bring a new therapeutic strategy to either alleviate the symptoms or kill the virus. There are too many attempts to name them all, but we will focus on a limited number of the most promising ones. Check our Latest News page to see every-day new information!
The first-ever anti-COVID-19 medicine approved only in China, Favilavir, inhibits the RNA-dependent RNA polymerase (RdRp), and already has shown to help 340 coronavirus-infected patients enrolled in a clinical study from Wuhan and Shenzhen. More updates coming from them later.
I-Mab Biopharma is developing TJM2, a neutralising antibody, to treat cytokine storm in the severe cases of COVID-19 infection.
CytoDyn is filing for an investigational new drug (IND) application at the FDA to conduct a Phase 2 clinical trial with their HIV drug, leronlimab (PRO 140). It is a CCR5 receptor antagonist with the potential for multiple therapeutic directions, including COVID-19.It suppresses the inflammatory responses of the immune system by inhibiting regulatory lymphocytes and macrophages in the blood and other tissues.
Inovio and Ology Bioservices have partnered and received a $11.9 million grant from the Department of Defense for their novel DNA vaccine (INO-4800). Clinical trials have not yet begun.
Speaking of vaccines, this is the pivotal point of our march on COVID-19. Vaccines support our immune systems in fighting miscellaneous microbes, help the system recognize the pathogenic agents and antigens, and tune our organisms for a life-time immunity for specific infectious diseases (in many, but not all cases). Milken Institute has created an aggregation of publicly-available data resource for all treatments and vaccine programs currently in development.You will find over 70 treatment and 47 vaccine programs developed by American and overseas companies and research centers right here.
The battle rages on. We will be keeping you updated on a daily basis regarding new breakthroughs and revolutionary research results that will bring us closer toward the efficient, safe, and 100% effective treatment and vaccine.